| Code | CSB-RA023994MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to IBI-356, targeting TNFSF4 (tumor necrosis factor superfamily member 4), also known as OX40 ligand (OX40L). TNFSF4 is a cell surface protein primarily expressed on activated antigen-presenting cells, including dendritic cells, B cells, and macrophages. It functions as a critical costimulatory molecule in the immune system by binding to its receptor OX40 on activated T cells, promoting T cell proliferation, survival, and cytokine production. TNFSF4 plays an important role in modulating immune responses and has been implicated in various conditions including autoimmune diseases, inflammatory disorders, and cancer, where OX40-OX40L interactions contribute to both anti-tumor immunity and immune-related pathologies.
IBI-356 represents a therapeutic antibody designed to modulate the OX40-OX40L pathway, making this biosimilar a valuable tool for investigating TNFSF4-mediated immune regulation. This antibody enables researchers to explore costimulatory signaling mechanisms, study immune cell activation pathways, and investigate potential therapeutic interventions in immunological research and oncology studies.
There are currently no reviews for this product.